ABSTRACT New treatments proposed for patients with Duchenne muscular dystrophy (DMD) have their efficacy evaluated by lower limb tests. However, upper limb function tests evaluate both ambulatory (A)
Full dataset for Figure 4 from "Clearance of human IgG1-sensitised red blood cells in vivo in humans relates to the in vitro properties of antibodies from alternative cell lines."
